Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide Plus Everolimus in mCRPC
NCT02125084Phase 1Completed
- Sponsor
- SCRI Development Innovations
- Start
- Oct 2014
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of everolimus in metastatic castration-resistant prostate cancer (mCRPC), sponsored by SCRI Development Innovations. Primary endpoints: Maximum Tolerated Dose, Prostate-Specific Antigen Response Rate and 2 more. Started Oct 2014; status: completed.
02
Drugs
everolimus
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02125084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02125084.